Allemailem K, Almatroudi A, Alrumaihi F, Alradhi A, Theyab A, Algahtani M
Int J Nanomedicine. 2024; 19:10185-10212.
PMID: 39399829
PMC: 11471075.
DOI: 10.2147/IJN.S479068.
Zheng J, Zhu Y, Huang T, Gao W, He J, Huang Z
Sci China Life Sci. 2024; 67(9):1781-1791.
PMID: 38842649
DOI: 10.1007/s11427-024-2607-8.
Deng X, Sun W, Li X, Wang J, Cheng Z, Sheng G
Nat Commun. 2024; 15(1):1806.
PMID: 38418450
PMC: 10901769.
DOI: 10.1038/s41467-024-45987-5.
Wen S, Zhao Y, Qi X, Cai M, Huang K, Liu H
Comput Struct Biotechnol J. 2024; 23:537-548.
PMID: 38235361
PMC: 10791570.
DOI: 10.1016/j.csbj.2023.12.030.
Kawamata M, Suzuki H, Kimura R, Suzuki A
Nat Biomed Eng. 2023; 7(5):672-691.
PMID: 37037965
PMC: 10195680.
DOI: 10.1038/s41551-023-01011-7.
The Many (Inter)faces of Anti-CRISPRs: Modulation of CRISPR-Cas Structure and Dynamics by Mechanistically Diverse Inhibitors.
Belato H, Lisi G
Biomolecules. 2023; 13(2).
PMID: 36830633
PMC: 9953297.
DOI: 10.3390/biom13020264.
Anti-CRISPR AcrIIC5 is a dsDNA mimic that inhibits type II-C Cas9 effectors by blocking PAM recognition.
Sun W, Zhao X, Wang J, Yang X, Cheng Z, Liu S
Nucleic Acids Res. 2023; 51(4):1984-1995.
PMID: 36744495
PMC: 9976890.
DOI: 10.1093/nar/gkad052.
Temperature dependent in vitro binding and release of target DNA by Cas9 enzyme.
David S, Maheshwaram S, Shet D, Lakshminarayana M, Soni G
Sci Rep. 2022; 12(1):15243.
PMID: 36085316
PMC: 9463129.
DOI: 10.1038/s41598-022-19485-x.
Tips, Tricks, and Potential Pitfalls of CRISPR Genome Editing in .
Antony J, Hinz J, Wyrick J
Front Bioeng Biotechnol. 2022; 10:924914.
PMID: 35706506
PMC: 9190257.
DOI: 10.3389/fbioe.2022.924914.
KPT330 improves Cas9 precision genome- and base-editing by selectively regulating mRNA nuclear export.
Cui Y, Wang S, Ma T, Yu P, Chen J, Guo T
Commun Biol. 2022; 5(1):237.
PMID: 35301428
PMC: 8931069.
DOI: 10.1038/s42003-022-03188-0.
Discovery of potent and versatile CRISPR-Cas9 inhibitors engineered for chemically controllable genome editing.
Song G, Zhang F, Tian C, Gao X, Zhu X, Fan D
Nucleic Acids Res. 2022; 50(5):2836-2853.
PMID: 35188577
PMC: 8934645.
DOI: 10.1093/nar/gkac099.
Atomic-scale insights into allosteric inhibition and evolutional rescue mechanism of Cas9 by the anti-CRISPR protein AcrIIA6.
Li X, Wang C, Peng T, Chai Z, Ni D, Liu Y
Comput Struct Biotechnol J. 2021; 19:6108-6124.
PMID: 34900128
PMC: 8632846.
DOI: 10.1016/j.csbj.2021.11.010.
Inhibition mechanisms of CRISPR-Cas9 by AcrIIA17 and AcrIIA18.
Wang X, Li X, Ma Y, He J, Liu X, Yu G
Nucleic Acids Res. 2021; 50(1):512-521.
PMID: 34893860
PMC: 8754659.
DOI: 10.1093/nar/gkab1197.
Structure-based functional mechanisms and biotechnology applications of anti-CRISPR proteins.
Jia N, Patel D
Nat Rev Mol Cell Biol. 2021; 22(8):563-579.
PMID: 34089013
DOI: 10.1038/s41580-021-00371-9.
CRISPR/Cas System: A Potential Technology for the Prevention and Control of COVID-19 and Emerging Infectious Diseases.
Ding R, Long J, Yuan M, Jin Y, Yang H, Chen M
Front Cell Infect Microbiol. 2021; 11:639108.
PMID: 33968799
PMC: 8102830.
DOI: 10.3389/fcimb.2021.639108.
Efficient ssODN-Mediated Targeting by Avoiding Cellular Inhibitory RNAs through Precomplexed CRISPR-Cas9/sgRNA Ribonucleoprotein.
Kagita A, Lung M, Xu H, Kita Y, Sasakawa N, Iguchi T
Stem Cell Reports. 2021; 16(4):985-996.
PMID: 33711268
PMC: 8072016.
DOI: 10.1016/j.stemcr.2021.02.013.
Optogenetic control of Neisseria meningitidis Cas9 genome editing using an engineered, light-switchable anti-CRISPR protein.
Hoffmann M, Mathony J, Upmeier Zu Belzen J, Harteveld Z, Aschenbrenner S, Stengl C
Nucleic Acids Res. 2020; 49(5):e29.
PMID: 33330940
PMC: 7969004.
DOI: 10.1093/nar/gkaa1198.
Epigenome engineering: new technologies for precision medicine.
Sgro A, Blancafort P
Nucleic Acids Res. 2020; 48(22):12453-12482.
PMID: 33196851
PMC: 7736826.
DOI: 10.1093/nar/gkaa1000.
Discovery of multiple anti-CRISPRs highlights anti-defense gene clustering in mobile genetic elements.
Pinilla-Redondo R, Shehreen S, Marino N, Fagerlund R, Brown C, Sorensen S
Nat Commun. 2020; 11(1):5652.
PMID: 33159058
PMC: 7648647.
DOI: 10.1038/s41467-020-19415-3.
Base editing: advances and therapeutic opportunities.
Porto E, Komor A, Slaymaker I, Yeo G
Nat Rev Drug Discov. 2020; 19(12):839-859.
PMID: 33077937
PMC: 7721651.
DOI: 10.1038/s41573-020-0084-6.